133 In the index

Octreotide OCTR

An FDA-approved medication used for a growth-hormone disorder (acromegaly), certain tumors, and other conditions involving excess hormone release. Extensive research strongly confirms it works well for these approved uses.

Also known as Sandostatin

Effects Hormonal

Routes Subcutaneous

Legal status Prescription drug

WADA Not listed

Molecular Structure of C₄₉H₆₆N₁₀O₁₀S₂

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C49H66N10O10S2
Molar mass: 1019.2
CAS: 83150-76-9
PubChem CID: 448601

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 100-200 mcg, 2-3 times daily (immediate-release) or 20-30 mg monthly (long-acting)

Reported range 50-500 mcg per dose, or 10-40 mg monthly depending on formulation

Route Subcutaneous injection or intramuscular injection (long-acting)

Frequency 2-3 times daily (immediate-release) or once monthly (long-acting depot)

Duration Chronic/ongoing (as prescribed)

FDA-approved somatostatin analog (Sandostatin) for acromegaly and certain tumors.

Where this comes from FDA prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.